Enhertu demonstrated median PFS of 13.2 months in IHC 1+ or IHC 2+/ISH- metastatic breast cancer in phase III trial

The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives
In a time of uncertainty, “react to the knowns, not the fear”

Thomas J. Lynch Jr. and Howard A. “Skip” Burris III lead two institutions that couldn’t be more different—an NCI-designated Comprehensive Cancer Center on one side of the country and a for-profit research enterprise on the other—but they stay up at nights worrying about the same thing.

Breast implant closes reconstruction gap for patients after mastectomy

Johnson & Johnson MedTech on May 13 announced the U.S. launch of MENTOR MemoryGel Enhance Breast Implants, filling a critical gap in comprehensive breast cancer care for women who have undergone a mastectomy.

May 16, 2025

Vol.51 No.19

Clinical Roundup

Incidence rates of some cancer types have risen in people under age 50, NCI study shows

Researchers at NCI have completed a comprehensive analysis of cancer statistics for different age groups in the United States and found that from 2010 through 2019, the incidence of 14 cancer types increased among people under age 50.

May 09, 2025

Vol.51 No.18

Advancing quality of life in oncology: A journey of compassion and innovation

The recent ASCO guideline update on palliative care for cancer patients represents a significant milestone in our field’s evolution. This evidence-based guidance emphasizes what I’ve advocated throughout my career—that palliative care must be integrated early and concurrently throughout the cancer journey. This holistic approach to cancer care has been my life’s work and passion.

David Ryan named president of Mass General Brigham Cancer Institute

David Ryan was named the inaugural president of the Mass General Brigham’s Cancer Institute following a national search process.

May 02, 2025

Vol.51 No.17

Cancer Policy

ASCO seeks to engage new leaders of NIH, CMS, and FDA

The Association for Clinical Oncology has reached out to the new leaders of federal health agencies to ensure continued progress in cancer care, research, and patient access, the organization said.

April 25, 2025

Vol.51 No.16

By Jacquelyn Cobb

Enhertu demonstrated median PFS of 13.2 months in IHC 1+ or IHC 2+/ISH- metastatic breast cancer in phase III trial

YOU MAY BE INTERESTED IN

The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives
In a time of uncertainty, “react to the knowns, not the fear”

Breast implant closes reconstruction gap for patients after mastectomy

Incidence rates of some cancer types have risen in people under age 50, NCI study shows

Advancing quality of life in oncology: A journey of compassion and innovation

David Ryan named president of Mass General Brigham Cancer Institute

ASCO seeks to engage new leaders of NIH, CMS, and FDA

Renew today!

Subscriber content

Never miss an issue!

Login

Enhertu demonstrated median PFS of 13.2 months in IHC 1+ or IHC 2+/ISH- metastatic breast cancer in phase III trial

YOU MAY BE INTERESTED IN

The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient livesIn a time of uncertainty, “react to the knowns, not the fear”

Breast implant closes reconstruction gap for patients after mastectomy

Incidence rates of some cancer types have risen in people under age 50, NCI study shows

Advancing quality of life in oncology: A journey of compassion and innovation

David Ryan named president of Mass General Brigham Cancer Institute

ASCO seeks to engage new leaders of NIH, CMS, and FDA

Never miss an issue!

Login

The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives
In a time of uncertainty, “react to the knowns, not the fear”